Emergent BioSolutions Inc. - 10-Q Summary (Period Ended June 30, 2009)
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for Emergent BioSolutions Inc. for the period ended June 30, 2009. Emergent is a biopharmaceutical company focused on biodefense and commercial vaccines and therapeutics. Its primary revenue source is the sale of BioThrax (Anthrax Vaccine Adsorbed) to the U.S. Department of Health and Human Services (HHS) and the Department of Defense (DoD). The company operates two segments: Biodefense and Commercial.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2009 |
Six Months Ended June 30, 2009 |
|---|---|---|
| Total Revenues | $73,191 | $137,710 |
| Net Income (Attributable to Emergent) | $14,842 | $25,961 |
| Operating Income | $22,710 | $39,976 |
| Cash and Cash Equivalents | $102,508 (as of June 30, 2009) | |
| Total Debt Outstanding | $55.6 million principal | |
| Net Cash Provided by Operating Activities | $20,462 (Six Months) |
Margins (Six Months Ended June 30, 2009):
- Gross Margin: Approximately 81% (Calculated as Total Revenues $137.7M minus Cost of Product Sales $25.8M).
- Operating Margin: Approximately 29%.
- Effective Tax Rate: Approximately 40%.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 68% year-over-year for the three months ended June 30, 2009 ($73.2M vs. $43.5M) and 60% for the six months ($137.7M vs. $86.2M). This was driven primarily by a $29.6 million lump-sum payment from HHS related to FDA approval extending BioThrax expiry dating from three to four years, plus increased pricing on delivered doses.
- Profitability: Net income attributable to Emergent surged to $14.8M for the quarter (from $1.8M in 2008) and $26.0M for the six months (from $8.8M in 2008).
- Impairment Charge: The company recorded a $3.8 million impairment charge related to two buildings in Frederick, Maryland, which were classified as "assets held for sale."
- Joint Venture Losses: The Oxford-Emergent Tuberculosis Consortium (OETC) incurred a net loss of $5.2 million for the six months, with $2.5 million attributable to noncontrolling interest.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- BioThrax Contracts: The company is fulfilling a contract to supply 18.75 million doses to the Strategic National Stockpile (SNS), with deliveries completed in July 2009. A new contract for up to 14.5 million doses is expected to commence deliveries in September 2009.
- Manufacturing: A new 50,000 sq. ft. facility in Lansing, Michigan, is being converted to manufacture the recombinant protective antigen (rPA) anthrax vaccine candidate. The company is also in the process of selling its Frederick, MD facilities and purchasing a new facility in Maryland.
- Development Pipeline: Significant R&D spending continues on anthrax therapeutics (immune globulin, monoclonal antibody) and commercial candidates (tuberculosis, typhoid, botulism).
Risks and Contingencies:
- Government Dependence: Substantially all revenue is derived from U.S. government contracts. Future funding is subject to Congressional appropriations and competitive bidding.
- Protein Sciences Corporation (PSC) Litigation: Emergent is engaged in litigation and bankruptcy proceedings against PSC regarding a $10 million loan. Emergent has filed a bankruptcy petition against PSC and seeks full repayment plus interest.
- Regulatory & Manufacturing: Risks include FDA inspection outcomes, manufacturing yield issues, and the complexity of biologics production. The company relies on a single contract filler for BioThrax vials.
- Legal Proceedings: Ongoing lawsuits regarding BioThrax use by the military and potential product liability claims, though the company relies on statutory protections (PREP Act, SAFETY Act) and indemnification.
Investor Verification Checklist
- Contract Renewals: Verify the status of the new HHS contract for 14.5 million BioThrax doses and the timeline for the rPA vaccine procurement contract.
- Asset Sale Closure: Confirm the closing date and net proceeds from the sale of the Frederick, Maryland facilities.
- PSC Litigation Outcome: Monitor the bankruptcy proceedings against Protein Sciences Corporation to assess the recoverability of the $10 million note receivable.
- Manufacturing Capacity: Assess the timeline for FDA approval of the new Lansing facility for rPA production and the impact on BioThrax supply.
- Debt Covenants: Review the terms of the $55.6 million debt outstanding, particularly the revolving line of credit and mortgage loans, to ensure compliance with covenants.